PLSE — PULSE BIOSCIENCES, INC.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1625101 ·
Last close
$26.00
Market Cap
$1.80B
52W High
$27.98
52W Low
$17.46
ADV30
338,656
Next earnings
2026-05-04
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026
Dec 2025 264,000 4,000 -18,253,000 -17,433,000 94,539,000 80,735,000 13,883,000
Sep 2025 86,000 -193,000 -20,367,000 -19,385,000 108,765,000 95,214,000 16,071,000
Jun 2025 0 -20,275,000 -19,168,000 120,251,000 106,349,000 15,764,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-54,122,000
Investing CF
$-335,000
Financing CF
$17,154,000
CapEx
$-335,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.10
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-463,281,000
Inventory
$136,000
Receivables
$274,000
ST Investments
EBIT TTM
$-76,939,000
Pretax Income TTM
$-72,781,000
Interest Exp TTM
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$751,000
EBITDA
$-76,402,000
Free Cash Flow
$-29,080,124
Enterprise Value
$1,730,675,456
Total Cash
$68,319,000
Total Debt
$7,155,000
Shares Out
69,209,712
Trailing EPS
$-1.10
Book Value
$1.19
ROE
-80.7%
ROA
-45.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 350,000 -76,939,000 -72,781,000 94,539,000 13,883,000 -54,122,000
Dec 2024 0 -56,257,000 -53,585,000 132,460,000 17,598,000 -36,343,000
Dec 2023 0 -43,574,000 -42,210,000 59,154,000 14,794,000 -33,041,000
Dec 2022 700,000 -58,057,000 -58,505,000 77,877,000 80,125,000 -47,013,000

TTM Snapshot

Revenues TTM
$1,148,000
NetIncome TTM
$-51,071,000
OpCashFlow TTM
$0
Assets (Latest)
$54,249,000
Forward EPS
$-0.88

Peers — same industry

TickerNameMarket CapLastDaily %
UFPT UFP TECHNOLOGIES INC $1.77B $229.06
XRAY DENTSPLY SIRONA Inc. $2.00B $9.99
PRCT PROCEPT BioRobotics Corp $1.56B $27.45
NVCR NovoCure Ltd $2.11B $18.26
ESTA ESTABLISHMENT LABS HOLDINGS INC. $2.14B $72.64

News headlines (Yahoo Finance, 1h cache)

Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy
2026-05-26 16:00 · Yahoo
Pulse Biosciences CEO Bought 15,000 Company Shares. Here's What That Means for Investors.
2026-05-17 15:02 · Yahoo
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
2026-05-12 11:00 · Yahoo
Is Pulse Biosciences (PLSE) Quietly Redefining Its Core Identity Around Atrial Fibrillation?
2026-05-10 16:08 · Yahoo
Pulse Biosciences Q1 Earnings Call Highlights
2026-05-08 20:05 · Yahoo
PLSE Q1 2026 Earnings Transcript
2026-05-08 14:18 · Yahoo
Pulse Biosciences to Present at the BofA Securities 2026 Healthcare Conference
2026-05-08 11:00 · Yahoo
Pulse Biosciences (PLSE) Upgraded to Buy: What Does It Mean for the Stock?
2026-05-07 16:00 · Yahoo
Turbett Surgical Appoints Kevin Danahy as President and Chief Executive Officer to Lead Growth Phase
2026-05-06 12:00 · Yahoo
PLSE Q4 2025 Earnings Transcript
2026-05-04 20:32 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.